Latest News
Pillar Biosciences introduces oncoReveal Myeloid v2 Panel
6 October 2026 - US biotechnology company Pillar Biosciences on Monday announced the launch of the oncoReveal Myeloid v2 Panel, an expanded research-use-only (RUO) DNA next-generation sequencing (NGS) panel for myeloid malignancies.According to Pilla...
Zydus and MSN announce US launch of generic Adempas (Riociguat Tablets)
6 October 2026 - India-based pharmaceutical companies Zydus Lifesciences Limited and MSN Laboratories Private Limited announced on Monday the launch of Riociguat Tablets, 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg, in the United States.Zydus and MSN say t...
AbbVie and Genmab report positive results from epcoritamab Phase 3 study in diffuse large B-cell lymphoma
6 October 2026 - US pharmaceutical company AbbVie (NYSE:ABBV) and Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a ...
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
6 October 2026 - Mozart Therapeutics Inc, a developer of CD8 Treg network modulators for the treatment of autoimmune disease, announced on Monday the presentation of clinical and preclinical data for its lead development programme, MTX-101, at the 62...
Moberg Pharma reports new Phase 3 analyses on terbinafine activity in onychomycosis
5 October 2026 - Swedish pharmaceutical company Moberg Pharma AB (STO: MOB) on Monday announced that it has published new analyses showing potent antifungal activity of terbinafine against dermatophytes causing onychomycosis.The company said its topi...